 |
366 Diseases |  |
40 Trials |
|
40 Trials |  |
1659 News |  |
| «12...7891011121314151617...2223» |
- | Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial primary completion date: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Sep 18, 2018
P2, N=73, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2019 --> Jun 2018
- ||| Torisel (temsirolimus) / Pfizer
Trial completion: Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) - Sep 17, 2018
P=N/A, N=133, Completed, Sponsor: Pfizer
Trial primary completion date: Feb 2019 --> Jun 2018 Active, not recruiting --> Completed
- ||| Torisel (temsirolimus) / Pfizer
Trial completion, Enrollment change: Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) (clinicaltrials.gov) - Sep 17, 2018
P=N/A, N=1022, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=600 --> 1022
- | Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date: Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours (clinicaltrials.gov) - Sep 7, 2018
P1, N=7, Active, not recruiting, Sponsor: Canadian Cancer Trials Group
Active, not recruiting --> Completed | N=600 --> 1022 Trial completion date: May 2020 --> Dec 2018 | Trial primary completion date: Feb 2019 --> Sep 2017
- ||| Torisel (temsirolimus) / Pfizer
Trial completion: Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 15, 2018
P4, N=101, Completed, Sponsor: Pfizer
Trial completion date: May 2020 --> Dec 2018 | Trial primary completion date: Feb 2019 --> Sep 2017 Active, not recruiting --> Completed
- || Torisel (temsirolimus) / Pfizer
Trial completion, Trial completion date, Trial primary completion date: Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) - Aug 15, 2018
P2, N=37, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Dec 2018 --> Jan 2018
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Biomarker, P2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. (Pubmed Central) - Aug 15, 2018
PFS was not significantly increased in any experimental arm compared to historical controls. NRG Oncology/Gynecologic Oncology Group Study GOG-86P.
- | Recentin (cediranib) / AstraZeneca, Torisel (temsirolimus) / Pfizer
Trial completion date, Metastases: AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies (clinicaltrials.gov) - Jul 27, 2018
P1, N=50, Active, not recruiting, Sponsor: Susana M. Campos, MD
NRG Oncology/Gynecologic Oncology Group Study GOG-86P. Trial completion date: Apr 2018 --> Dec 2018
- | Torisel (temsirolimus) / Pfizer
Enrollment closed: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) - Jul 24, 2018
P3, N=253, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2018 --> Dec 2018 Suspended --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - Jul 20, 2018
P1, N=52, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Active, not recruiting Trial completion date: Aug 2020 --> Sep 2022 | Trial primary completion date: Aug 2020 --> Sep 2021
- | ganetespib (ADX-1612) / Aldeyra
Trial completion, Enrollment change, Trial completion date, Combination therapy, Metastases: SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) (clinicaltrials.gov) - Jul 17, 2018
P1/2, N=20, Completed, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial completion date: Aug 2020 --> Sep 2022 | Trial primary completion date: Aug 2020 --> Sep 2021 Active, not recruiting --> Completed | N=38 --> 20 | Trial completion date: Apr 2018 --> Jul 2018
- | pimasertib (AS703026) / Day One Biopharma, Torisel (temsirolimus) / Pfizer
Clinical, P1 data, Journal: Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. (Pubmed Central) - Jul 13, 2018
P1
Seventeen patients (17/26 patients) had a best response of stable disease; five had stable disease lasting >12 weeks. Conclusions The RP2D was not defined and the pimasertib plus temsirolimus combination investigated did not warrant further study.
- | erlotinib / Generic mfg., Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Torisel (temsirolimus) / Pfizer
Clinical, P1 data, Journal, Combination therapy: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. (Pubmed Central) - Jul 13, 2018
P1
Overlapping toxicities prevented the escalation of selumetinib to its recommended phase II monotherapy dose of 75 mg BID. ClinicalTrials.gov NCT00600496; registered 8 July 2009.
- | Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Jul 3, 2018
P1/2, N=92, Completed, Sponsor: National Cancer Institute (NCI)
ClinicalTrials.gov NCT00600496; registered 8 July 2009. N=31 --> 92
- | Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) (clinicaltrials.gov) - Jul 2, 2018
P1/2, N=33, Terminated, Sponsor: Western Regional Medical Center
N=31 --> 92 N=49 --> 33 | Trial completion date: Apr 2018 --> Nov 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Nov 2017; Investigator no longer at site to enroll patients or write up data
- | Votrient (pazopanib) / Novartis, Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
New trial: COMBOREIN: Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=100, Recruiting, Sponsor: University Hospital, Grenoble
- || Torisel (temsirolimus) / Pfizer
Trial completion, Trial completion date, Trial primary completion date, Metastases: Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) (clinicaltrials.gov) - Jun 18, 2018
P1/2, N=48, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
N=49 --> 33 | Trial completion date: Apr 2018 --> Nov 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Nov 2017; Investigator no longer at site to enroll patients or write up data Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Jun 2018 | Trial primary completion date: Nov 2019 --> Jun 2018
- | cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy, Metastases: Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 13, 2018
P1/2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Jun 2018 | Trial primary completion date: Nov 2019 --> Jun 2018 Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion: Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Jun 3, 2018
P1/2, N=115, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial suspension: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) - Jun 2, 2018
P3, N=253, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Suspended
- ||| Enrollment change, Tumor mutational burden, BRCA Biomarker, MSi-H Biomarker, PARP Biomarker, PD(L)-1 Biomarker, Metastases: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (clinicaltrials.gov) - May 31, 2018
P2, N=1440, Recruiting, Sponsor: American Society of Clinical Oncology
Recruiting --> Suspended N=1060 --> 1440
- || Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO) (clinicaltrials.gov) - May 31, 2018
P2, N=60, Recruiting, Sponsor: Mercator MedSystems, Inc.
N=1060 --> 1440 Trial primary completion date: Mar 2018 --> Sep 2018
- | Nutlin-3 / EMD Serono, Torisel (temsirolimus) / Pfizer, ABT-737 / AbbVie
Journal, Combination therapy: High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. (Pubmed Central) - May 10, 2018
Mapping the signaling networks revealed that combinations of two inhibitors increased the number of affected proteins in the targeted pathways and in multiple parallel signaling, translating into facilitated cell death. These results demonstrated that mechanism-based selection of combined inhibitors can be used to guide clinical drug selection and tailor treatment regimens to eliminate microenvironment-mediated resistance in acute myeloid leukemia.
- | cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Apr 20, 2018
P2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
These results demonstrated that mechanism-based selection of combined inhibitors can be used to guide clinical drug selection and tailor treatment regimens to eliminate microenvironment-mediated resistance in acute myeloid leukemia. Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Metastases: Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) (clinicaltrials.gov) - Apr 18, 2018
P1/2, N=48, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- | Torisel (temsirolimus) / Pfizer
Phase classification, Metastases: A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Apr 17, 2018
P1, N=12, Completed, Sponsor: City of Hope Medical Center
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Phase classification: P=N/A --> P1
- | Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - Apr 3, 2018
P1, N=114, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P=N/A --> P1 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion date, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Mar 30, 2018
P1, N=216, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Mar 2020 --> Mar 2021
- | tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Hakko Kirin, Merck (MSD), Torisel (temsirolimus) / Pfizer
Clinical, P1 data, Journal, Combination therapy: A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. (Pubmed Central) - Mar 25, 2018
Pharmacokinetic analysis showed that there is no interaction in the plasma concentrations between tivantinib and temsirolimus. Conclusions The combination of tivantinib with temsirolimus appears to be well tolerated with evidence of clinical activity.
- | Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Trial completion date, Metastases: A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours (clinicaltrials.gov) - Mar 22, 2018
P2, N=137, Active, not recruiting, Sponsor: Canadian Cancer Trials Group
Conclusions The combination of tivantinib with temsirolimus appears to be well tolerated with evidence of clinical activity. Trial completion date: Dec 2017 --> Dec 2018
- |||| Enrollment open, Tumor mutational burden, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, Pan tumor: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (clinicaltrials.gov) - Mar 16, 2018
P2, N=720, Recruiting, Sponsor: Canadian Cancer Trials Group
Trial completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- | NLG207 / Ellipses Pharma, Avastin (bevacizumab) / Roche
Clinical, P2 data, Journal, Combination therapy: A randomized phase 2 trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. (Pubmed Central) - Mar 4, 2018
P2
Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2)...Further development in this disease is not planned. NCT02187302 (NIH).
- | Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion date, Combination therapy, Metastases: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) (clinicaltrials.gov) - Mar 3, 2018
P1, N=140, Active, not recruiting, Sponsor: AstraZeneca
NCT02187302 (NIH). Trial completion date: Dec 2017 --> Dec 2018
- | Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date: Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Feb 22, 2018
P1, N=18, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Oct 2018 --> Oct 2019 | Trial completion date: Oct 2018 --> Oct 2020
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Torisel (temsirolimus) / Pfizer
Enrollment change, Trial primary completion date, Surgery, Metastases: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 8, 2018
P1, N=22, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2018 --> Oct 2019 | Trial completion date: Oct 2018 --> Oct 2020 N=30 --> 22 | Trial primary completion date: Jun 2017 --> Feb 2017
- | Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: CRUK-08/015: Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium (clinicaltrials.gov) - Feb 6, 2018
P1/2, N=15, Completed, Sponsor: Cardiff University
N=30 --> 22 | Trial primary completion date: Jun 2017 --> Feb 2017 N=99 --> 15
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Journal: Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. (Pubmed Central) - Feb 2, 2018
N=99 --> 15 The combination of bevacizumab, cetuximab, and temsirolimus showed activity in HNSCC; however, there were numerous toxicities reported, which will require careful management for future clinical development.
- | Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Trial primary completion date, Metastases: Phase II Study of Alternating Sunitinib and Temsirolimus (clinicaltrials.gov) - Jan 30, 2018
P2, N=37, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
The combination of bevacizumab, cetuximab, and temsirolimus showed activity in HNSCC; however, there were numerous toxicities reported, which will require careful management for future clinical development. Trial primary completion date: Dec 2016 --> Dec 2018
- | Torisel (temsirolimus) / Pfizer
Clinical, PK/PD data, Journal: Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. (Pubmed Central) - Jan 24, 2018
This study is the first to describe a population PK model of temsirolimus combined with sirolimus formation and disposition in paediatric patients. The developed model will facilitate PK model-based dose individualization of temsirolimus and the design of future clinical studies in children.
- | Torisel (temsirolimus) / Pfizer
Enrollment change: Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 17, 2018
P1/2, N=110, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
The developed model will facilitate PK model-based dose individualization of temsirolimus and the design of future clinical studies in children. N=150 --> 110
- | prednisone / Generic mfg., everolimus / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Metastases: PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI (clinicaltrials.gov) - Jan 16, 2018
P2, N=8, Terminated, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
N=150 --> 110 N=42 --> 8 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> May 2017
- | Torisel (temsirolimus) / Pfizer
Enrollment open: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (clinicaltrials.gov) - Jan 10, 2018
P3, N=337, Recruiting, Sponsor: National Cancer Institute (NCI)
N=42 --> 8 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> May 2017 Suspended --> Recruiting
- || Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Trial primary completion date, Stroma, Metastases: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=1600, Recruiting, Sponsor: Pfizer
Suspended --> Recruiting Trial primary completion date: Sep 2019 --> Dec 2023
- | Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Jan 9, 2018
P1/2, N=74, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Sep 2019 --> Dec 2023 Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial primary completion date, Combination therapy, Metastases: Temsirolimus in Combination With Metformin in Patients With Advanced Cancers (clinicaltrials.gov) - Jan 9, 2018
P1, N=104, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Mar 2018 --> Mar 2020
- Torisel (temsirolimus) / Pfizer
Trial primary completion date: Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) - Jan 3, 2018
P2, N=40, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Mar 2018 --> Mar 2020 Trial primary completion date: Dec 2017 --> Dec 2018
- Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Enrollment closed, Enrollment change, Metastases: A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours (clinicaltrials.gov) - Dec 29, 2017
P2, N=137, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | N=210 --> 137
- | Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial initiation date, Trial primary completion date, Metastases: Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Dec 20, 2017
P2, N=40, Completed, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Active, not recruiting | N=210 --> 137 Initiation date: Jan 2009 --> Apr 2009 | Trial primary completion date: Jul 2016 --> May 2015
- | Torisel (temsirolimus) / Pfizer
New trial, Metastases: FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=16, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
- | perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Trial termination: Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma (clinicaltrials.gov) - Dec 19, 2017
P1/2, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2009 --> Apr 2009 | Trial primary completion date: Jul 2016 --> May 2015 Active, not recruiting --> Terminated